Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

Also called NCT03961360

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 220 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03961360
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03961360. Randomized; no masking; primary purpose treatment. Start 2019-05-06 (actual); primary completion 2023-04-10 (actual). Results posted on 2024-05-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
Acronym
ASPREO
Condition
Pre-Eclampsia
Condition
Hypertension in Pregnancy
Condition
Obesity
Intervention (Drug)
Aspirin 81 mg
Intervention (Drug)
Aspirin 162 mg
Lead sponsor
The University of Texas Health Science Center, Houston (class: other)

Record details

Record id
cardio:ct-nct03961360
Content hash
92e0b7c5db16e0e14da2f51835acea417684faf945d2804ea8d4227f33ba3c20